Intensive treatment for the progression of joint damage in rheumatoid arthritis patients with low disease activity or remission

被引：0
作者：
Mochizuki, Takeshi [1 ,4 ]
Koenuma, Naoko [2 ]
Yano, Koichiro [2 ]
Ikari, Katsunori [2 ,3 ]
Hiroshima, Ryo [1 ]
Okazaki, Ken [2 ]
机构：
[1] Kamagaya Gen Hosp, Dept Orthopaed Surg, Chiba, Japan
[2] Tokyo Womens Med Univ, Dept Orthopaed Surg, Tokyo, Japan
[3] Tokyo Womens Med Univ, Div Multidisciplinary Management Rheumat Dis, Tokyo, Japan
[4] Kamagaya Gen Hosp, Dept Orthopaed Surg, 929-6 Hatsutomi, Kamagaya, Chiba 2730121, Japan
来源：
MODERN RHEUMATOLOGY | 2024年 / 34卷 / 02期
关键词：
Intensive treatment; joint damage; low disease activity; remission; rheumatoid arthritis; AMERICAN-COLLEGE; METHOTREXATE; THERAPY; DRUG;
D O I：
10.1093/mr/road041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Objectives To investigate the effects of intensive treatment on joint damage in patients with rheumatoid arthritis (RA) showing progression of joint damage and low disease activity or remission. Methods Eighty-nine patients who had change in the van der Heijde modified total Sharp score (TSS) of >0.5 points at baseline when compared with the score 1 year ago were enrolled and categorized into two groups to receive intensive (intensive group) or current (current group) treatment. The intensive and current groups were compared for change (Delta) from baseline to 1 year of erosion score, joint space narrowing score, and TSS. Results The Delta TSS values at 1 year in the intensive and current groups were 0.67 +/- 1.09 and 1.79 +/- 1.70, respectively (P < 0.001). In the intensive and current groups, the Delta TSS <= 0.5 at 1 year were 66.7% and 32.4%, respectively (P = 0.010). Conclusions The intensive treatment was more effective at suppressing joint damage than the current treatment. The progression of joint damage is an important target to consider for intensive treatment.
引用
收藏
页码：329 / 333
页数：5
相关论文
共 20 条
  • [1] Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment
    Aletaha, D.
    Funovits, J.
    Breedveld, F. C.
    Sharp, J.
    Segurado, O.
    Smolen, J. S.
    [J]. ARTHRITIS AND RHEUMATISM, 2009, 60 (05): : 1242 - 1249
  • [2] An Explanation for the Apparent Dissociation Between Clinical Remission and Continued Structural Deterioration in Rheumatoid Arthritis
    Brown, A. K.
    Conaghan, P. G.
    Karim, Z.
    Quinn, M. A.
    Ikeda, K.
    Peterfy, C. G.
    Hensor, E.
    Wakefield, R. J.
    O'Connor, P. J.
    Emery, P.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (10): : 2958 - 2967
  • [3] Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI [10.1136/ard.2011.149765, 10.1002/art.30129]
  • [4] 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
    Fraenkel, Liana
    Bathon, Joan M.
    England, Bryant R.
    St Clair, E. William
    Arayssi, Thurayya
    Carandang, Kristine
    Deane, Kevin D.
    Genovese, Mark
    Huston, Kent Kwas
    Kerr, Gail
    Kremer, Joel
    Nakamura, Mary C.
    Russell, Linda A.
    Singh, Jasvinder A.
    Smith, Benjamin J.
    Sparks, Jeffrey A.
    Venkatachalam, Shilpa
    Weinblatt, Michael E.
    Al-Gibbawi, Mounir
    Baker, Joshua F.
    Barbour, Kamil E.
    Barton, Jennifer L.
    Cappelli, Laura
    Chamseddine, Fatimah
    George, Michael
    Johnson, Sindhu R.
    Kahale, Lara
    Karam, Basil S.
    Khamis, Assem M.
    Navarro-Millan, Iris
    Mirza, Reza
    Schwab, Pascale
    Singh, Namrata
    Turgunbaev, Marat
    Turner, Amy S.
    Yaacoub, Sally
    Akl, Elie A.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (07) : 1108 - 1123
  • [5] Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug A Randomized Clinical Trial
    Gottenberg, Jacques-Eric
    Brocq, Olivier
    Perdriger, Aleth
    Lassoued, Slim
    Berthelot, Jean-Marie
    Wendling, Daniel
    Euller-Ziegler, Liana
    Soubrier, Martin
    Richez, Christophe
    Fautrel, Bruno
    Constantin, Arnaud L.
    Mariette, Xavier
    Morel, Jacques
    Gilson, Melanie
    Cormier, Gregoire
    Salmon, Jean Hugues
    Rist, Stephanie
    Liote, Frederic
    Marotte, Hubert
    Bonnet, Christine
    Marcelli, Christian
    Sellam, Jeremie
    Meyer, Olivier
    Solau-Gervais, Elisabeth
    Guis, Sandrine
    Ziza, Jean-Marc
    Zarnitsky, Charles
    Chary-Valckenaere, Isabelle
    Vittecoq, Olivier
    Saraux, Alain
    Pers, Yves-Marie
    Gayraud, Martine
    Bolla, Gilles
    Claudepierre, Pascal
    Ardizzone, Marc
    Dernis, Emmanuelle
    Breban, Maxime A.
    Fain, Olivier
    Balblanc, Jean-Charles
    Aberkane, Ouafaa
    Vazel, Marion
    Back, Christelle
    Candon, Sophie
    Chatenoud, Lucienne
    Perrodeau, Elodie
    Sibilia, Jean
    Ravaud, Philippe
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (11): : 1172 - 1180
  • [6] Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice
    Katayama, Kou
    Okubo, Takanobu
    Sato, Toshikazu
    Ito, Hiroshi
    Fukai, Richio
    Baba, Hisashi
    [J]. MODERN RHEUMATOLOGY, 2015, 25 (01) : 50 - 55
  • [7] Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage
    Khanna, D
    Ranganath, VK
    FitzGerald, J
    Park, GS
    Altman, RD
    Elashoff, D
    Gold, RH
    Sharp, JT
    Furst, DE
    Paulus, HE
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (08): : 2284 - 2292
  • [8] Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission
    Kuriya, B.
    Arkema, E. V.
    Bykerk, V. P.
    Keystone, E. C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (07) : 1298 - 1304
  • [9] Continuously elevated serum matrix metalloproteinase-3 for 3 ∼ 6 months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study
    Ma, Jian-Da
    Wei, Xiu-Ning
    Zheng, Dong-Hui
    Mo, Ying-Qian
    Chen, Le-Feng
    Zhang, Xiang
    Li, Jing-Hua
    Dai, Lie
    [J]. ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [10] The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis
    Matsuno, Hiroaki
    Okada, Masato
    Sakai, Yoshitada
    Abe, Chiyuki
    Katayama, Kou
    Sagawa, Akira
    Yamasaki, Kuniomi
    Kondo, Masakazu
    Funahashi, Keiko
    Matsubara, Tsukasa
    [J]. MODERN RHEUMATOLOGY, 2016, 26 (01) : 51 - 56
12